Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

NCT03552276 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries Limited as lead sponsor.

NCT NCT03552276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03552276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Lead sponsor
Sun Pharmaceutical Industries Limited
Phase
Phase 2/3
Overall status
Completed
Start date
July 11, 2018
Completion date
September 18, 2023
Enrollment
281 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis